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Abstract
Background: It has been hypothesized that reduced axonal transport contributes to the degeneration of
neuronal processes in Parkinson's disease (PD). Mitochondria supply the adenosine triphosphate (ATP)
needed to support axonal transport and contribute to many other cellular functions essential for the
survival of neuronal cells. Furthermore, mitochondria in PD tissues are metabolically and functionally
compromised. To address this hypothesis, we measured the velocity of mitochondrial movement in human
transmitochondrial cybrid "cytoplasmic hybrid" neuronal cells bearing mitochondrial DNA from patients
with sporadic PD and disease-free age-matched volunteer controls (CNT). The absorption of low level,
near-infrared laser light by components of the mitochondrial electron transport chain (mtETC) enhances
mitochondrial metabolism, stimulates oxidative phosphorylation and improves redox capacity. PD and
CNT cybrid neuronal cells were exposed to near-infrared laser light to determine if the velocity of
mitochondrial movement can be restored by low level light therapy (LLLT). Axonal transport of labeled
mitochondria was documented by time lapse microscopy in dopaminergic PD and CNT cybrid neuronal
cells before and after illumination with an 810 nm diode laser (50 mW/cm2) for 40 seconds. Oxygen
utilization and assembly of mtETC complexes were also determined.
Results: The velocity of mitochondrial movement in PD cybrid neuronal cells (0.175 +/- 0.005 SEM) was
significantly reduced (p < 0.02) compared to mitochondrial movement in disease free CNT cybrid
neuronal cells (0.232 +/- 0.017 SEM). For two hours after LLLT, the average velocity of mitochondrial
movement in PD cybrid neurites was significantly (p < 0.003) increased (to 0.224 +/- 0.02 SEM) and
restored to levels comparable to CNT. Mitochondrial movement in CNT cybrid neurites was unaltered
by LLLT (0.232 +/- 0.017 SEM). Assembly of complexes in the mtETC was reduced and oxygen utilization
was altered in PD cybrid neuronal cells. PD cybrid neuronal cell lines with the most dysfunctional mtETC
assembly and oxygen utilization profiles were least responsive to LLLT.
Conclusion: The results from this study support our proposal that axonal transport is reduced in
sporadic PD and that a single, brief treatment with near-infrared light can restore axonal transport to
control levels. These results are the first demonstration that LLLT can increase axonal transport in model
human dopaminergic neuronal cells and they suggest that LLLT could be developed as a novel treatment
to improve neuronal function in patients with PD.
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Background
Sporadic Parkinson's disease (PD) is a disabling, progres-
sive neurodegenerative disease. The neuropathological
characterization of PD includes not only the loss of
dopaminergic neurons in the substantia nigra and other
brainstem nuclei but also the presence of cytoplasmic
inclusions that form Lewy bodies and Lewy neurites in
surviving neurons. [1,2] Degeneration of nigral neurons
begins at synaptic terminals and progresses retrograde to
cell bodies before the onset of symptoms. [3] At symptom
onset, 60–80% of the striatal dopaminergic terminals
have already been lost. Dopaminergic nerve terminals
continue to be lost at a rate of 10–12% a year. [4]
Neurons prone to degeneration in PD have axons that are
long and poorly myelinated and provide a massive inner-
vation to the striatum (150,000 presynaptic terminals per
neuron). [5] Neurons have a high metabolic rate and
require a large, uninterrupted supply of ATP. [6] Microtu-
bule-based anterograde axonal transport is ATP-driven
and responsible for the delivery of mitochondria and
other cellular constituents to distal sites in neurons. Com-
promised retrograde axonal transport deprives the cell
body of vital trophic factors and deprives axons and den-
drites of synaptic vesicles, lysosomes and mitochondria.
[5,7]
Reduced or compromised axonal transport could underlie
the progressive, relentless loss of dopaminergic nerve ter-
minals in sporadic PD. Axonal transport is one aspect of
mitochondrial dynamics that is critical for the distribu-
tion of functional mitochondria to distal synaptic termi-
nals. Movement, fission, and fusion of mitochondria are
functions that are also essential for neuronal survival. [8]
Studies at the ultrastructural level in human PD caudate
and striatum detected a disruption in the distribution of
both microtubules and organelles such as mitochondria.
[9] Neurotoxins that are used to model PD pathogenesis
(1-methyl-4-phenylpyridinium (MPP+) and rotenone)
compromise mitochondrial function by inhibiting com-
plex I of the mtETC. These toxins also have microtubule
depolymerizing activities that alter axonal transport.
[2,10-14] Complex I of the mtETC is structurally and func-
tionally defective in brain, platelets and other tissues in
PD patients. [15,16] Since mitochondrial DNA (mtDNA)
encodes components of the mtETC, it is not surprising
that mtDNA from PD patients contains increased levels of
mutations and deletions. [15,17-19]
It is now known that genes linked to familial PD (α-synu-
clein, parkin and PINK1) play important roles in mito-
chondrial transport dynamics and function. [8,20]
Pathogenic mutation, hyper-phosphorylation or over-
expression of α-synuclein is associated with reduced
axonal transport. [21] Liang et al [13] and Feng [22] sug-
gested that the consequences of both genetic and environ-
mental risk factors for familial and sporadic PD disrupt
microtubules and axonal transport, leading to the death
of dopaminergic neurons.
In an effort to explore the contribution of mitochondria
to features of PD pathogenesis such as reduced axonal
transport, we have focused our studies on "cytoplasmic
hybrid" cybrid cell lines. Cybrid cell lines were created by
the fusion of donated platelets from PD or CNT volun-
teers with human mtDNA-free (Rho0) SH-SY5Y human
neuroblastoma or NT2 teratocarcinoma cells. [23,24]
Cybrid cell lines have been used to explore the role of
mitochondrial dysfunction in PD. [24-28] Using this
model of PD pathogenesis, the contribution of mitochon-
dria can be selectively studied and the variability due to
nuclear genes and environmental factors can be control-
led. [29]
Changes in PD cybrid cell lines correlate with changes
seen in PD brain. [29] PD cybrid lines exhibit- A)
decreased complex I activity,[26,28] B) increased produc-
tion of reactive oxygen species (ROS),[26,28,30] C)
increased levels of antioxidant enzymes,[26,31] D)
increased numbers of morphologically abnormal mito-
chondria,[32] E) mtDNA with deletions (personal com-
munication, Dr. Bradley Miller), and F) fibrillar and
vesicular inclusions called cybrid Lewy bodies that repli-
cate the essential antigenic and structural features of Lewy
bodies in PD brain. [27]
Non-dividing, process-bearing, dopaminergic neuronal
cells were generated from undifferentiated CNT and PD
cybrids using a low concentration of staurosporine. [2,33]
These PD and CNT cybrid neuronal cells contain neuronal
cytoskeletal proteins (neuron-specific beta tubulin, tau,
and microtubule associated protein 2) and dopaminergic
markers (tyrosine hydroxylase, dopamine transporter, the
dopamine D2 receptor and the vesicular monoamine
transporter). [2] Our results show that the velocity of
mitochondrial movement is significantly reduced in the
processes of PD cybrid neuronal cells compared to CNT.
Reduced movement of mitochondria in human PD cybrid
neuronal cells supports the proposition that reduced
axonal transport plays a role in PD progression.
In an effort to normalize this reduction in mitochondrial
movement, we exposed PD and CNT cybrid neuronal cells
to a low level near-infrared light therapy. In animal stud-
ies, low level near-infrared light therapy (LLLT) improved
the outcome in retinal damage due to methanol or roten-
one toxicity, [33-35] traumatic brain injury,[36] or spinal
cord injury,[37] and induced analgesia in dorsal root gan-
glion neurons. [38] LLLT has improved the survival and
function of rat neuronal cells exposed to MPP+ [39] orMolecular Neurodegeneration 2009, 4:26 http://www.molecularneurodegeneration.com/content/4/1/26
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rotenone. [35] In the human brain, transcranial laser ther-
apy (delivery of near-infrared laser light through the scalp
and skull) has been used to successfully treat complex
neurological conditions such as ischemic stroke. [40]
Research supports the idea that near-infrared laser (750–
1400 nm) light is absorbed and stimulates components in
the mtETC, increases redox capacity, activates cytochrome
c oxidase (complex IV), increases ATP production in dys-
functional cells and initiates long-term changes in neuro-
nal function in human and animal studies. [37,40-43]
Our results show that a single treatment with 810 nm laser
light was sufficient to restore the velocity of mitochon-
drial movement to control levels in PD cybrid neuronal
cells.
Methods
Patient population
The demographics for PD and CNT volunteers were
described previously. [27] The Hoehn and Yahr[44] score
for all PD volunteers was stage 2. The mean age for the PD
group was 72.14 +/- 4.18SD and 64.4 +/- 5.68SD for the
CNT group.
Cybrid growth and differentiation
PD and CNT cybrid cell lines were created by fusing plate-
lets from sporadic PD or disease-free CNT individuals
with mtDNA-free Rho0 cells created in SH-SY5Y neurob-
lastoma cells. [45] Blood samples were collected under an
IRB-approved protocol, and details of cybrid creation
were described previously. [27] PD and CNT cybrid, SH-
SY5Y and Rho0 cell lines were grown in T75 tissue culture
flasks (Greiner, PGC Scientific, Gaithersburg, MD) in a
culture medium (CM) consisting of Dulbecco's modified
Eagle's medium with high glucose (DMEM), 10% charac-
terized fetal bovine serum (FBS, Hyclone, Logan, Utah),
100 μg/ml pyruvate, 50 μg/ml uridine, antibiotic-antimy-
cotic, 100 Units/ml penicillin G, 100 μg/ml streptomycin,
0.25  μg/ml and amphotericin β (Invitrogen, Carlsbad,
California, USA). [27]
Cybrid neuron differentiation
Glass bottomed 35 mm dishes (MatTek Corp., Ashland,
MA) were washed with sterile H2O then treated with ster-
ile 1 N HCl for 30 minutes, washed three times with sterile
H2O and stored at room temperature (RT). Coverslip
dishes were coated for 40 min.-overnight with 1.5 mg/ml
poly-l-lysine (PL, Sigma-Aldrich, St. Louis, Missouri, USA)
dissolved in sterile RT H2O. Dishes were rinsed twice with
sterile RT H2O before adding the cell suspension.
Proliferating cybrid cells were harvested from flasks with
0.05% trypsin (Invitrogen, Carlsbad, CA) in phosphate
buffered saline (PBS, Sigma-Aldrich, St. Louis, Missouri,
USA) for 5 minutes at 37°C. Trypsin activity was stopped
by an equal volume of CM. Cells were then centrifuged at
200 g for 5 minutes and re-suspended in CM. 40,000 cells
in 2 ml CM were added to each 35 mM dish. After 18–24
hours, CM was removed and the differentiation media
(DM, 500 ml of Neurobasal with 10 ml B27 supplements
[Invitrogen, Carlsbad, CA] and 0.5 mM glutamine, pyru-
vate, uridine and antibiotic-antimycotic as described
above). A 25 μM stock solution of staurosporine (ST,
Sigma-Aldrich Corp, St Louis, Missouri, USA) was made
in dimethyl sulfoxide, frozen at -80°C. Unused aliquots
were discarded after 60 days. ST (4 nM-8 nM) dilutions
were made fresh in DM and replaced every 2–3 days. Dif-
ferentiation was completed on day 12.
Immunocytochemistry
The MitoProfile® OXPHOS/PDH immunocytochemistry
kit (MitoSciences, Eugene, Oregon, USA) was used to
detect defective assembly of ETC complexes I-V. The man-
ufacturer's suggested protocol was modified for coverslip
dishes. Vectashield mounting medium (Vector Labs, Bur-
lingame, California, USA) was added to coverslip dish
after staining. Images of stained cybrid neuronal cells were
created using an Olympus Fluoview laser scanning confo-
cal microscope system (Center Valley, Pennsylvania,
USA). SYTO 61 (Invitrogen) at a concentration of 5 mM
(30 min) was used to stain nucleic acids in the cell nucleus
and cytoplasm.
High Resolution Oxygen Respirometry
A two chamber oxygraph O2k (Oroboros, Innsbruck, Aus-
tria) was used to measure respiration rates of dissociated
CNT, PD and laser-treated CNT and PD cybrid neuronal
cells according to manufacturers directions. After 12 days
in DM, PD and CNT cybrid neuronal cells were harvested
by rinsing with PBS. The cells (4.5 × 106 cells/ml resus-
pended in phenol-free DMEM and separated into two
sterile 35 mm culture dishes) were kept on ice. In this
blinded study, one dish received LLLT (see below) and the
other dish remained untreated for each cybrid line stud-
ied. After the oxygraph was calibrated according to manu-
facturer's instructions, 2 ml of LLLT or untreated cybrid
neuronal cells were added to each chamber. The chambers
were closed and cells were equilibrated (37°C). After the
basal rate of respiration was established, complex V respi-
ration was inhibited by oligomycin (4 ug/ml final concen-
tration). Respiration was uncoupled by carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP at a final
concentration of ~0.325 uM, Sigma St Louis, MO). Com-
plex 1 was inhibited by adding rotenone at a final concen-
tration of 1.0 μM.
Axonal transport
To measure mitochondrial movement, cybrid neuronal
cells were incubated with 50 nM MitoTracker CMXRos
(MTRed; Invitrogen, Carlsbad, California, USA) for 10
min at 37°C. [46] Time-lapse recordings were made usingMolecular Neurodegeneration 2009, 4:26 http://www.molecularneurodegeneration.com/content/4/1/26
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an Olympus IX70 microscope equipped with epifluores-
cence and Nomarski optics, a Lambda 10-2 filter wheel, a
Photometrics CoolSnap HQ progressive scan CCD cam-
era and a heater/controller to maintain cybrid cells at
37°C during image collection (World Precision Instru-
ments, Inc, Sarasota, Florida, USA). Collection of image
stacks, and velocity measurements were made using Met-
aMorph Imaging System (Molecular Devices, Downing-
town, Pennsylvania, USA). For standard recordings,
images were collected every 3 seconds for 2 min. Unlike
other studies, the velocity of all mitochondria in each cell
process was tracked by hand whether they moved or not.
The average velocity for individual mitochondria was cal-
culated using intervals where movement occurred. [46]
Neutral density filters are used to reduce illumination
from the mercury lamp and minimize phototoxicity. [46]
LLLT with near-infrared 810 nm laser
Differentiated neuronal cells from cultures of six PD and
five CNT cybrid lines as well as SH-SY5Y were labeled with
MtRed in phenol-free DM and 10–15 movies (1–3 neur-
ites per movie, 8–50 mitochondria per process) were col-
lected per dish. A second dish from each line was switched
to phenol-free DM and uniformly illuminated at 50 mW/
cm2 (measured at the dish surface) with a continuous
wave 810nm diode laser for 40 seconds (Acculaser, Pho-
toThera, Inc, Carlsbad, California, USA). The power out-
put of the laser was measured before each LLLT
experiment with an Ohir Optronics power meter (Jerusa-
lem, Israel) to ensure consistent exposure. After LLLT, neu-
ronal cells from six PD, five CNT and SH-SY5Y lines were
stained with MTRed as described above. Movies (n = 10–
15 movies per experimental condition, 2–3 processes/
movie, 8–50 mitochondria per process) were collected at
5 to 10 minute intervals for at least 2 hours for each dish
(n = 2–3 experiments +/- LLLT per cybrid line). T-tests
assuming equal or unequal variance were used as needed
to analyze the data.
Results
Mitochondrial movement in differentiated PD and CNT 
cybrid neurites
The processes selected for study in all conditions were
comparable in length and diameter (Figure 1). The range
of mitochondrial lengths in PD, CNT and LLLT-treated
cybrids was not qualitatively different (Figure 1). Mito-
chondrial movement in PD, CNT and LLLT and untreated
cybrid neurites was bidirectional but primarily antero-
grade and saltatory (see Additional file 1, Additional file
2, Additional file 3, Additional file 4). The number of
mitochondria moving retrograde in any process was min-
imal. Consequently, velocity was measured irrespective of
direction. Average velocities for individual mitochondria
less than or equal to 0.075 μm/second were categorized as
stationary. In CNT cybrids, 14% of the mitochondria were
stationary during the recording period. The number of sta-
tionary mitochondria in PD cybrid neurites was elevated
compared to CNT cybrid neurites (29%, see Table 1). As
shown in Table 1 and Figure 2, the average velocity of
mitochondrial movement in PD cybrid neurites (0.175 +/
- 0.005SEM) was significantly less than the velocity in
CNT cybrid neurites (0.232 +/- 0.017SEM). The total
Table 1: Data from studies of mitochondrial movement in LLLT and untreated PD and CNT cybrid neurons
PD
(n = 6)
SEM PD vs PD+LLLT
p value
CNT
(n = 5)
SEM PD vs CNT
p value
Velocity (μm/sec) 0.175 0.005 0.001 0.232 0.017 0.02
Percent not moving (v<0.075) 29 3.68 0.01 14 2.42 0.01
Average distance traveled 0.54 0.016 0.006 0.757 0.048 NS
Total distance traveled 9.92 0.261 0.004 17.09 1.18 0.004
Time spent moving (out of 120 sec) 45 0.358 NS 61 6.89 NS
Number of neurites/cybrid 24–53 26–44
PD + LLLT
(n = 6)
SEM CNT + LLLT
(n = 5)
SEM CNT vs CNT+LLLT
p value
LLLT-50 mW/cm2 for 40 sec (2J/cm2)
Velocity (μm/sec) 0.224 0.02 0.226 0.017 NS
Percent not moving (v<0.075) 12 2.15 16 2.15 NS
Average distance traveled 0.682 0.033 0.782 0.065 NS
Total distance traveled 12.78 0.616 16.34 1.27 NS
Time spent moving (out of 120 sec) 48 3.94 63 6.92 NS
Number of neurites/cybrid 25–51 28–58
Significance was determined using a two-tailed t test assuming unequal variance.Molecular Neurodegeneration 2009, 4:26 http://www.molecularneurodegeneration.com/content/4/1/26
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amount of time spent moving and the average distance
traveled by mitochondria in PD cybrid neurites was
reduced but not significantly different from CNT (Table 1,
Figure 2) however, the total distance traveled by mito-
chondria in PD cybrid neurites was significantly reduced
compared to CNT cybrid mitochondria (Figure 2).
Effects of LLLT on mitochondrial movement in 
differentiated PD and CNT cybrid neurites
For at least 2 hours after exposure to LLLT (Table 1 and
Figure 2), the velocity of mitochondrial movement in PD
cybrid neurites was significantly increased and restored to
CNT levels. This change in velocity was achieved by reduc-
ing the number of stationary mitochondria and increasing
the average and total distance traveled (Table 1 and Figure
2). Further studies are needed to determine if more indi-
vidual stationary mitochondria initiate movement after
LLLT or if mitochondria already in motion exhibit
increased velocity. The total time PD mitochondria spent
moving after LLLT was not significantly different from
CNT (Table 1). Of the six PD cybrid lines studied, the
response of two lines (PD60, PD61) to LLLT was consist-
ently increased but did not achieve significance in three
separate studies. Mitochondrial movement in the five
CNT cybrid lines also did not change significantly in
response to LLLT (Table 1 and Figure 2).
mtETC assembly in PD, CNT and LLLT-treated cybrid 
neuronal cells
To better understand the role that mitochondrial dysfunc-
tion plays in mitochondrial movement, we double
stained differentiated PD and CNT cybrid neuronal cells
with antibodies to essential components of mtETC com-
plexes I-V. The presence of staining with monoclonal anti-
bodies directed against labile subunits of each complex
(CI-NDUFB4, CII-30 kDa, CIII-Core 2 protein, CIV-subu-
nit I, CV-OSCP) indicates that the complex is correctly
assembled. [47] By double staining with antibodies to a
These montages illustrate the movements of MTRed-labeled mitochondria in the processes of CNT68, CNT68-90 minutes  after LLLT, PD63 and PD63-85 minutes after LLLT Figure 1
These montages illustrate the movements of MTRed-labeled mitochondria in the processes of CNT68, 
CNT68-90 minutes after LLLT, PD63 and PD63-85 minutes after LLLT. Moving mitochondria in each montage are 
indicated by arrowheads, arrows, circles and boxes. The images were taken every 3 seconds. Original movies are shown as 
additional files. Bar = 1 μm.Molecular Neurodegeneration 2009, 4:26 http://www.molecularneurodegeneration.com/content/4/1/26
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control subunit (CV α), it was possible to calculate the
percentage of cybrid neuronal cells that had intact assem-
bly of complexes I-V (Figure 3). All five complexes were
correctly assembled in CNT cybrid neuronal cells (data
not shown). PD cybrid neuron lines (PD60, PD61) exhib-
ited an increase mitochondrial movement after LLLT that
did not achieve significance. The same lines also exhibited
low levels of complexes I and IV assembly as well as
reduced assembly in two other complexes (Figure 3). In
contrast, the four PD cybrids (PD63, PD65, PD66, PD67)
that exhibited a significant response to LLLT contained
more cybrid neuronal cells with correctly assembled com-
plexes I and IV (50–100%). In these four PD lines, at least
three complexes were correctly assembled which suggests
that the mtETC was more functional (Figure 3).
Oxygen utilization studies
An Oxygraph 2K (Oroboros) [48] was used to measure
changes in oxygen utilization by Rho0 cells that lack a
functional mtETC, two lines of PD cybrid neuronal cells
(PD60 and PD61) that did not respond significantly to
LLLT, two lines of PD cybrid neuronal cells (PD65 and
PD66) that did respond significantly to LLLT and a CNT
line (CNT91) of cybrid neuronal cells. These data are
shown in Figure 4. Rho0 cells, PD60 and PD61 had
reduced routine aerobic respiration (Figure 4A), capacity
of the mtETC (Figure 4C) and complex I mediated respi-
ration (Figure 4E) compared to CNT91. [see [48] for
details] Non-phosphorylating (oligomycin-inhibited) res-
piration (LEAK, Figure 4B) did not vary greatly among any
of the cell lines tested; however the residual oxygen con-
This figure contains three graphs Figure 2
This figure contains three graphs. Graph 2A depicts the average velocity of mitochondrial movement in the processes of 
CNT (n = 5), CNT+LLLT (n = 5), PD (n = 6) and PD+LLLT (n = 6) cybrid neuronal cell lines. Using a two-tailed t-test assuming 
unequal variance, mitochondrial movement in PD cybrid neurites was significantly reduced compared to CNT. Mitochondrial 
movement in PD+LLLT cybrid neurites was significantly increased compared to PD. Mitochondrial movment in CNT cybrid 
neurites was not significantly different from CNT+LLLT. Differences in culture conditions, cell type, mitochondrial labeling 
method and method of velocity calculation make it difficult to compare mitochondrial velocities among published papers. 
Graph 2B depicts the average distance traveled by mitochondria during the recording period. The average distance traveled by 
mitochondria (calculated by averaging the distance traveled for each three second interval irrespective of direction of travel) in 
PD+LLLT was significantly increased above PD. Graph 2C depicts the total distance traveled (calculated by summing the dis-
tance traveled in each three second interval irrespective of direction of travel) during the recording period by mitochondria in 
each category. The total distance traveled by PD mitochondria was significantly reduced compared to CNT. The total distance 
traveled by PD+LLLT mitochondria were significantly increased compared to PD.Molecular Neurodegeneration 2009, 4:26 http://www.molecularneurodegeneration.com/content/4/1/26
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sumption (ROX, Figure 4D) was higher in Rho0, PD60
and PD61 lines compared to PD65, PD66 or CNT91. In
contrast CNT91, PD65 and PD66 had higher routine aer-
obic respiration, mtETC capacity, and complex I mediated
respiration (Figures 4A, 4C and 4E) as well as a reduced
level of ROX (Figure 4D). The respiratory control ratio
(RCR) which reveals the relative efficiency of ETC cou-
pling (Figure 4F) was diminished in Rho0, PD60 and
PD61 compared to cybrid lines that responded signifi-
cantly to LLLT (PD65, PD66 and CNT91). During the two
hour period of measurement after LLLT there was no sta-
tistically significant change in respiratory chain activity in
any of the cybrid lines tested using the Oxygraph-2k (data
not shown).
Discussion
In this study we showed that the velocity of mitochondrial
movement by axonal transport was significantly reduced
in a human neuronal model of sporadic PD. Other studies
have also suggested a role for reduced axonal transport in
the pathogenesis of PD. Our data lends additional sup-
port for this proposition and for the role that dysfunc-
tional mitochondria play in early PD pathogenesis. We
also showed that a single treatment with near-infrared
laser light can restore the velocity of mitochondrial move-
ment in PD cybrid neuronal cells to CNT levels. LLLT with
near-infrared laser light has been proven safe and effective
for the treatment of complex neurological conditions like
stroke in humans and rodents. [40,49] Our results pro-
The montage in 3A shows PD61 cybrid neuronal cells stained with the MitoProfile® OXPHOS/PDH immunocytochemistry kit  (MitoSciences) Figure 3
The montage in 3A shows PD61 cybrid neuronal cells stained with the MitoProfile® OXPHOS/PDH immuno-
cytochemistry kit (MitoSciences). Specific antibodies (FITC secondary antibody, green) to Complex I-NDUFB4 (A-C), 
Complex II-30 kDa (D-F), Complex III-Core 2 protein (G-I), Complex IV-subunit I (J-L), and Complex V-OSCP (M-O) were 
combined with antibodies to a control subunit (CVα, Texas red secondary, red) to double stain mitochondria in cybrid neuro-
nal cells (see methods). The cell bodies were stained with SYTO 61 (blue). Cybrid neuronal cells in the first column that exhibit 
double staining are orange or yellow and have intact mETC assembly while cybrid neuronal cells that lack intact assembly of 
complexs in the mETC are red. Bar = 20 μm. The graph in 3B depicts counts of PD cybrid neuronal cells that contained fully 
assembled mtETC complexes. In this graph Complex I is black, Complex II has diagonal stripes, Complex III is light gray, Com-
plex IV has horizontal stripes, and Complex V is dark gray. The CNT cybrid neuronal cells exhibited complete assembly of all 
five complexes (data not shown).Molecular Neurodegeneration 2009, 4:26 http://www.molecularneurodegeneration.com/content/4/1/26
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vide essential data to support the exploration of LLLT with
near-infrared laser light for treatment of neurological con-
ditions like PD.
The mitochondria in PD cybrids exhibit structural and
functional changes that could interfere with normal
movement of mitochondria by axonal transport or con-
tribute to the differential response of PD cybrid mito-
chondria to LLLT. These include-1) reduced activity of
complexes I and IV, 2) increased levels of oxidized and
nitrated proteins, 3) insufficient ATP, 4) a swollen and
abnormal morphology, 5) increased levels of modified α-
synuclein, and 6) increased free/polymerized tubulin
ratio. [24,28,50,51]
A substantial body of evidence supports the proposal that
complex I dysfunction plays a critical role in PD patho-
genesis. [52] Analysis of the mtETC revealed reduced
assembly of complex I in five out of six PD cybrid neuro-
nal cell lines (Figure 3). Previous studies suggest that
mtETC subunit expression was also altered in sporadic PD
brain. [30] Complex I subunits were also oxidatively dam-
aged and this damage correlated with decreased function
in sporadic PD brain. [30] Findings of reduced capacity of
the electron transport chain, routine respiration and com-
plex I mediated oxygen utilization (Figure 4) in PD cybrid
neuronal cells, complimented our mtETC assembly data.
CNT91 cybrid neuronal cells had oxygen utilization rates
comparable to fibroblasts, peritoneal mesothelial cells
and hematopoetic cells. [48,53,54]
Complex IV is also misassembled in four out of six PD
cybrid lines (Figure 3). Reduced complex IV activity and
increased levels of nitrated proteins have been detected in
PD tissue and in PD cybrid lines[24,27]. Studies have sug-
gested that nitrative damage plays an important role in
PD. [55] Both complexes I and IV are targets of NO. [43]
Treatment of neuronal cultures with NO reduces the
movement of mitochondria and synaptic vesicles; there-
fore, it is reasonable to propose that nitrative damage to
the mtETC contributes to the loss of mitochondrial move-
ment in PD cybrids. [56-58]
While the degree of mtETC misassembly in each PD
cybrid line did not correlate with mitochondrial velocity,
mtETC misassembly did relate to the response of PD
cybrid neuronal cells to LLLT. All the PD cybrid neuronal
cells showed increased mitochondrial velocity after LLLT;
The graphs in this figure illustrate the levels of routine (basal) respiration (A), nonphosphorylating leak (oligomycin inhibited)  respiration (B), capacity of the electron transport chain in nonpermeablized cells (C), residual oxygen consumption or ROX  (D), maximum uncoupled respiration mediated by complex I (E) and the respiratory control ratio (F) in Rho0 cells, and  selected PD and CNT cybrid neuron lines Figure 4
The graphs in this figure illustrate the levels of routine (basal) respiration (A), nonphosphorylating leak (oligo-
mycin inhibited) respiration (B), capacity of the electron transport chain in nonpermeablized cells (C), resid-
ual oxygen consumption or ROX (D), maximum uncoupled respiration mediated by complex I (E) and the 
respiratory control ratio (F) in Rho0 cells, and selected PD and CNT cybrid neuron lines. The Y axis in Figures 4A-
E is Respiration [pmol O2/second/10-6 cells]. These data were calculated based on formulas described by Gnaiger. [48]Molecular Neurodegeneration 2009, 4:26 http://www.molecularneurodegeneration.com/content/4/1/26
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however the changes in PD60 and PD61 did not consist-
ently achieve significance (Figure 3). Current understand-
ing suggests that near-infrared light is absorbed by
photosensitizers such as the oxidized copper centers in
complex IV. This results in the excitation and transfer of
electrons to oxygen and the generation of low level
changes in ROS expression that activates cellular processes
through the release of transcription factors and altered
gene expression. [41,59,60] Near-infrared light can also
reverse the inhibition of complex IV and cellular respira-
tion caused by NO occupation of the oxygen site. [43]
Cybrid neuronal cells PD60 and PD61 had the lowest lev-
els of complex I and IV assembly of all our lines (Figure 3).
It's not surprising therefore that the PD cybrid lines with
the least intact complex I and IV assembly also have a lim-
ited response to near-infrared light. LLLT was able to sig-
nificantly increase mitochondrial movement in other less
crippled PD cybrid neuronal cells (Figure 3). LLLT did not
improve oxygen utilization in OxyGraph studies of
selected PD or CNT lines of cybrid neurons (data not
shown). The two hour period selected for this study may
not have been sufficient time for changes in mtETC activ-
ity to achieve detectable levels. Further studies will focus
on longer post-LLLT intervals.
The velocity of mitochondrial movement in CNT cybrid
neuronal cells was not altered by LLLT. LLLT also failed to
enhance respiratory function in control animals used for
a study of rotenone induced mitochondrial optic neurop-
athy. [35] Rojas et al[35] suggest that mitochondria that
are functioning at a maximal rate are unable to be further
stimulated by LLLT. On the other hand, if the mtETC is
partially inhibited or dysfunctional, LLLT can increase
electron flow by stimulating complex IV. [35] Therefore,
we were not surprised when the velocity of mitochondrial
movement in CNT cybrid neuronal cells did not respond
significantly to LLLT in our study.
Reduced ATP levels stemming from mtETC dysfunction
could also limit availability of ATP for use by the motors
that drive axonal transport. [61] Esteves et al[24] detected
reduced levels of ATP in their undifferentiated NT2 PD
cybrids. Recent studies have suggested regional increases
in ADP can trigger mitochondrial movement. [62] We
used the BioVision Research Products ApoSensor ADP/
ATP ratio assay kit (Mountain View, CA) to measure the
ADP/ATP ratio but could not detect consistently altered
levels of ATP or ADP levels (data not shown) in our PD
and CNT cybrid neuronal cells after LLLT. Further studies
are needed to verify the role reduced ATP or increased
ADP play in the reduced movement of mitochondria in
PD cybrid neuronal cells.
The mitochondria in valinomycin-treated cerebellar neu-
ronal cells were swollen and they blocked mitochondrial
movement. [63] The mitochondria in PD cybrid neurites
were not swollen or rounded (Figure 1) so the reduction
in movement can not be attributed to this cause. PD
cybrids did contain aggregated, oxidized [27] and phos-
phorylated α-synuclein (data not shown). In transfected
neuronal cells, Saha et al [64] showed that mutated and
phosphorylated  α-synuclein reduced axonal transport.
Modified α-synuclein may contribute to the reduction in
mitochondrial movement in PD cybrid neurites but it is
unlikely that LLLT could alter α-synuclein aggregation,
oxidation or phosphorylation in the period of time stud-
ied. Aggregates of α-synuclein can appear in PD cybrid
neurites and in rotenone-treated SH-SY5Y neuronal cells,
cause localized swelling that resembles a Lewy neurite and
disrupt movement of all mitochondria distal to the swell-
ing ([2] and data not shown). Lewy neurite-like swellings
were uncommon in PD cybrid neurites and did not
account for the reduced movement of mitochondria in PD
cybrid neuronal cells.
Conclusion
Speculation that reduced axonal transport plays a role in
PD pathogenesis has existed for some time. Our ability to
assess the role of axonal transport in PD has improved
recently with the development of appropriate models and
methods. The outcome of our studies of human cybrid
neuronal cells that contain mitochondria derived from
CNT and PD volunteers illustrates that axonal transport of
mitochondria is significantly reduced in PD cybrid neur-
ites. Reduced axonal transport could underlie the loss of
neurites through terminal degeneration and result in the
death of dopaminergic neuronal cells in PD. The observa-
tion that a single, low level exposure to LLLT can increase
the velocity of mitochondrial movement and restore it to
CNT levels in PD cybrid neurites is remarkable but con-
sistent with our current understanding of the mechanism
of LLLT. In a recent publication, behavioral, metabolic
and anatomic measures were improved in a dose-depend-
ent manner in a rat model of rotenone-induced optic neu-
ropathy. [35] LLLT is also currently used to treat a wide
range of human conditions that involve injury and
inflammation. Recent findings that LLLT can be used to
ameliorate the consequences of stroke in phase 2 clinical
trials suggest that LLLT with near-infrared light [40]
should be explored for the treatment of other neurological
diseases such as PD.
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